FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028446499> ?p ?o ?g. }

• W3028446499 abstract "The development of anti-drug antibodies (ADAs) is a common cause for treatment failure and hypersensitivity reactions for many biologics. The focus of this review is the development of ImmTOR, platform technology designed to prevent the formation of ADAs that can be applied broadly across a wide variety of biologics by inducing immunological tolerance with ImmTOR nanoparticles encapsulating rapamycin. The induction of tolerance is antigen-specific and dependent on the incorporation of rapamycin in nanoparticles and the presence of the antigen at the time of administration of ImmTOR. Evidence for the induction of specific immune tolerance versus general immune suppression is supported by the findings that: 1) ImmTOR induces regulatory T cells specific to the co-administered antigen; 2) tolerance can be transferred by adoptive transfer of splenocytes from treated animals to naïve recipients; 3) the tolerance is durable to subsequent challenge with antigen alone; and 4) animals tolerized to a specific antigen are capable of responding to an unrelated antigen. ImmTOR nanoparticles can be added to new or existing biologics without the need to modify or reformulate the biologic drug. The ability of ImmTOR to mitigate the formation of ADAs has been demonstrated for coagulation factor VIII in a mouse model of hemophilia A, an anti-TNF monoclonal antibody in a mouse model of inflammatory arthritis, pegylated uricase in hyperuricemic mice and in nonhuman primates, acid alpha-glucosidase in a mouse model of Pompe disease, recombinant immunotoxin in a mouse model of mesothelioma, and adeno-associated vectors in a model of repeat dosing of gene therapy vectors in mice and in nonhuman primates. Human proof-of concept for the mitigation of ADAs has been demonstrated with SEL-212, a combination product consisting of ImmTOR + pegadricase, a highly immunogenic enzyme therapy for the treatment of gout. ImmTOR represents a promising approach to preventing the formation of ADAs to a broad range of biologic drugs." @default.
• W3028446499 created "2020-05-29" @default.
• W3028446499 creator A5086215911 @default.
• W3028446499 date "2020-05-20" @default.
• W3028446499 modified "2023-10-16" @default.
• W3028446499 title "Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies" @default.
• W3028446499 cites W141905111 @default.
• W3028446499 cites W1531743481 @default.
• W3028446499 cites W153537846 @default.
• W3028446499 cites W1537741082 @default.
• W3028446499 cites W1543067030 @default.
• W3028446499 cites W1561987315 @default.
• W3028446499 cites W1966018233 @default.
• W3028446499 cites W1970238011 @default.
• W3028446499 cites W1976821928 @default.
• W3028446499 cites W1980637669 @default.
• W3028446499 cites W1981298448 @default.
• W3028446499 cites W1987802826 @default.
• W3028446499 cites W1994064996 @default.
• W3028446499 cites W1997254933 @default.
• W3028446499 cites W2000988825 @default.
• W3028446499 cites W2001051250 @default.
• W3028446499 cites W2008686731 @default.
• W3028446499 cites W2018762139 @default.
• W3028446499 cites W2020378442 @default.
• W3028446499 cites W2020398834 @default.
• W3028446499 cites W2024148297 @default.
• W3028446499 cites W2025343661 @default.
• W3028446499 cites W2029392819 @default.
• W3028446499 cites W2037870683 @default.
• W3028446499 cites W2054221694 @default.
• W3028446499 cites W2070538463 @default.
• W3028446499 cites W2085721994 @default.
• W3028446499 cites W2086437884 @default.
• W3028446499 cites W2088410491 @default.
• W3028446499 cites W2089941945 @default.
• W3028446499 cites W2090723639 @default.
• W3028446499 cites W2091777991 @default.
• W3028446499 cites W2091858933 @default.
• W3028446499 cites W2092747941 @default.
• W3028446499 cites W2098981367 @default.
• W3028446499 cites W2099289539 @default.
• W3028446499 cites W2106417556 @default.
• W3028446499 cites W2111577577 @default.
• W3028446499 cites W2114302659 @default.
• W3028446499 cites W2114533414 @default.
• W3028446499 cites W2114646110 @default.
• W3028446499 cites W2121397820 @default.
• W3028446499 cites W2128895268 @default.
• W3028446499 cites W2143609092 @default.
• W3028446499 cites W2149065814 @default.
• W3028446499 cites W2155024437 @default.
• W3028446499 cites W2157739158 @default.
• W3028446499 cites W2158500407 @default.
• W3028446499 cites W2161354474 @default.
• W3028446499 cites W2162166897 @default.
• W3028446499 cites W2190691856 @default.
• W3028446499 cites W2263798318 @default.
• W3028446499 cites W2269265106 @default.
• W3028446499 cites W2277515189 @default.
• W3028446499 cites W2291150896 @default.
• W3028446499 cites W2417110244 @default.
• W3028446499 cites W2472330471 @default.
• W3028446499 cites W2479129912 @default.
• W3028446499 cites W2504151231 @default.
• W3028446499 cites W2528199055 @default.
• W3028446499 cites W2582177931 @default.
• W3028446499 cites W2586724023 @default.
• W3028446499 cites W2596676407 @default.
• W3028446499 cites W2603828830 @default.
• W3028446499 cites W2734287351 @default.
• W3028446499 cites W2737080715 @default.
• W3028446499 cites W2747415234 @default.
• W3028446499 cites W2755815881 @default.
• W3028446499 cites W2783019558 @default.
• W3028446499 cites W2784147308 @default.
• W3028446499 cites W2789434908 @default.
• W3028446499 cites W2793000267 @default.
• W3028446499 cites W2806302066 @default.
• W3028446499 cites W2808509820 @default.
• W3028446499 cites W2884362356 @default.
• W3028446499 cites W2891145080 @default.
• W3028446499 cites W2894600652 @default.
• W3028446499 cites W2897020726 @default.
• W3028446499 cites W2906825220 @default.
• W3028446499 cites W2909145676 @default.
• W3028446499 cites W2916006516 @default.
• W3028446499 cites W2917646500 @default.
• W3028446499 cites W2999405793 @default.
• W3028446499 cites W41296863 @default.
• W3028446499 cites W4296259680 @default.
• W3028446499 cites W854864039 @default.
• W3028446499 doi "https://doi.org/10.3389/fimmu.2020.00969" @default.
• W3028446499 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7251066" @default.
• W3028446499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32508839" @default.
• W3028446499 hasPublicationYear "2020" @default.
• W3028446499 type Work @default.
• W3028446499 sameAs 3028446499 @default.
• W3028446499 citedByCount "34" @default.
• W3028446499 countsByYear W30284464992020 @default.

• next